| ASCRX | VSCIX | ASCRX / VSCIX | |
| Total Expense Ratio | 1.35 | 0.04 | 3,375% |
| Annual Report Gross Expense Ratio | 1.35 | 0.04 | 3,375% |
| Fund Existence | 22 years | 28 years | - |
| Gain YTD | 11.957 | 9.641 | 124% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 160M | 163B | 0% |
| Annual Yield % from dividends | 0.00 | 1.33 | - |
| Returns for 1 year | 9.83 | 7.58 | 130% |
| Returns for 3 years | 40.53 | 45.16 | 90% |
| Returns for 5 years | 8.53 | 36.24 | 24% |
| Returns for 10 years | 36.68 | 142.18 | 26% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GEMLX | 15.09 | 0.09 | +0.60% |
| Goldman Sachs Emerging Mkts Eq ex. Chn C | |||
| VVOAX | 23.82 | 0.03 | +0.13% |
| Invesco Value Opportunities A | |||
| RIGKX | 16.89 | 0.02 | +0.12% |
| Victory RS International R | |||
| RDCCX | 8.21 | N/A | N/A |
| Columbia Disciplined Value C | |||
| ETCHX | 45.92 | -0.35 | -0.76% |
| Eventide Healthcare & Life Sciences C | |||